Kornimate/medical-research-clean huggingface dataset:
grade-srm: genomic risk assessment and decisional evaluation for small renal masses

Conditions: Small Renal Mass; Kidney Tumor

Summary: purpose: the purpose of this study is to evaluate the role of renal mass biopsy on decision-making for patients presenting with clinical t1 kidney tumors. this study also incorporates integrated biomarker study to compare the genomic data obtained through biopsy tissue to genomic information from surgical data.

primary objective 1. to compare the decisional conflict between patients who undergo renal mass biopsy during their evaluation for srms versus those who do not. 2. to validate the concordance of rna sequencing (rnaseq) and genomic-based risk stratification molecular biomarkers between renal biopsy tissue and surgical (nephrectomy) specimen tissue. secondary objective 1. to characterize the impact of biopsy on patient reported anxiety and uncertainty, assessment of cancer care communication, and satisfaction with cancer care.

Eligibility criteria:
inclusion criteria: * ages 18 - 95 * have a small renal mass ≤7 cm on cross-sectional radiologic study evaluated at the university of north carolina (unc) urology or the unc cancer hospital. * has voluntarily provided signed informed consent to participate and hipaa authorization for the release of personal health information * willing and able to complete patient-reported outcome questionnaires * willing to have extra cores taken for research during the standard-of-care biopsy procedure * willing to allow surgical specimens to be used for research * willing to undergo a blood draw to evaluate for circulating tumor dna exclusion criteria * has staging information indicating locally advanced or metastatic disease. * presence of transplant kidney * unwilling or unable to complete informed consent * previous biopsy of small renal mass.

Keywords: genomic risk assessment small renal mass
intravenous regadenoson versus intravenous adenoscan® for fractional flow reserve (ffr)

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to demonstrate that intravenous regadenoson is equivalent to intravenous adenoscan® for the physiological assessment of intermediate coronary lesions.

this is a prospective open label, single center pilot trial that will evaluate regadenoson compared to adenoscan® to be given iv in the assessment of fractional flow reserve. forty eight subjects will be enrolled and get adenoscan® administered via iv followed by regadenoson iv.

Eligibility criteria:
inclusion criteria: * patients undergoing elective left heart catheterization * age ≥ 18 years (female not of child bearing potential) * able to provide written informed consent exclusion criteria: * contraindications to administration of either adenoscan® or regadenoson * high degree av block, sick sinus syndrome without a functioning pacemaker * symptomatic bradycardia * recent stemi (\< 5 days) * recent nstemi (\ 1000 iu * dipyridamole use within 24 hours * adenoscan® is contraindicated (hypersensitivity to adenoscan®, regadenoson, or aminophylline * known severe bronchoconstrictive lung disease

Keywords: left heart catheterization fractional flow reserve adenoscan® regadenoson
study to assess the potential for adrenal suppression following treatment with dsxs in patients with plaque psoriasis

Conditions: Plaque Psoriasis

Summary: an open label, safety study to assess the potential for adrenal suppression following maximal use treatment with dsxs administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.

1. the objective of this study is to evaluate the potential of dsxs to suppress hpa axis function in patients with moderate to severe plaque psoriasis 2. to evaluate the efficacy parameters, pharmacokinetics and adverse event (ae) profile of dsxs

Eligibility criteria:
inclusion criteria: 1. patients with a confirmed diagnosis of plaque psoriasis, patients 2-17 years of age with ≥ 10% bsa affected and patients age 18 years of age or older with ≥ 20% bsa affected 2. investigator global assessment (iga) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity. 3. results from a cortisol response test that are considered normal and show no evidence of any abnormal hpa function or adrenal response exclusion criteria: 1. patients under 2 years of age. 2. investigator global assessment (iga) of less than 3 (moderate) or greater than 4 (severe) at baseline. 3. current diagnosis of types of psoriasis other than stable plaque psoriasis (i.e., erythrodermic, exfoliative or pustular psoriasis). 4. results from a cortisol response test that show evidence of any abnormal hpa function or adrenal response
evaluation of a new mechanical ventilation weaning strategy for patients with altered level of consciousness

Conditions: Artificial Respiration; Consciousness Disorders; Wearing Off Effect

Summary: the purpose of this study is to determine if a weaning strategy from artificial ventilation governs by respiratory behaviour status assessed by our method is safe enough.

current guidelines for mechanical ventilation weaning do not apply for patients with altered level of consciousness. one major limitation is a failure of clinical assessment of the respiratory behaviour status of these patients that are not able to interact appropriately with the examiner. we propose a non-invasive method for the respiratory behaviour assessment of a patient under artificial ventilation that do not requires his participation. our hypothesis is that, in case of normal respiratory behaviour status, it is possible to wean under security a patient despite his abnormal level of consciousness.we previously demonstrate that patients successfully wean by the clinical team also disclose a normal respiratory behaviour status while patients with weaning failure had abnormal respiratory behaviour. in the present study, we wonder to evaluate that a weaning strategy governs by respiratory behaviour status assessed by our method is safe. for this purpose, in this study, tracheal tube withdrawal is triggered by a recognition of a normal respiratory behaviour status assessed daily in patients under mechanical ventilation with an altered level of consciousness and a good tolerance to t tube challenge.

Eligibility criteria:
inclusion criteria: * altered level of consciousness (-1 \ +1) * mechanical ventilation ( \> 72 hours) * withdrawal of sedative drugs (\> 48 hours) * t tube challenge tolerance * signed approval for the study by close relative or legal representative exclusion criteria: * respiratory disease prior to the actual artificial ventilation requirement. * impairment of upper airway function prior to the actual artificial ventilation requirement. * pregnancy * minor

Keywords: altered level of consciousness tracheal tube withdrawal respiration artificial respiration physiology
prospective observation of failure patterns in nsclc treated with icis

Conditions: NSCLC Stage IV; NSCLC, Recurrent

Summary: by prospectively observing the time to the best therapeutic effect of non-small cell lung cancer after ici treatment, the characteristics of lesion distribution when the best therapeutic effect is reached, and the phenotype of disease progression after ici treatment response, the investigators intended to explore the failure pattern of nsclc after the once effective ici treatment. the investigators also aim to evaluate the feasibility and clinical value of radiotherapy for the treatment of oligo-progressive lesions after ici.


Eligibility criteria:
inclusion criteria (part i): * age between 18 and 75 years. * ecog ps 0-1. * pathologically confirmed stage iv nsclc. * negative for driver genes including egfr, alk, and ros-1. * patients achieved pr or cr after ici treatment, as defined by recist 1.1. * patients with complete radiological information of baseline lesions. * life expectancy of more than 3 months. * ability to understand and willingness to provide the informed consent. exclusion criteria (part i): * severe autoimmune disease or other contradictions to ici treatment. * mixed small cell with non-small cell lung cancer histology. * driver gene positive, including egfr, alk, and ros-1. * pregnant or lactating women. * history of any other malignancy. * active infection, congestive heart failure, myocardial infarction within the 6 months prior to enrollment, unstable angina pectoris or cardiac arrhythmia. * patients receiving immunosuppressive agents,or other investigational treatment. long-term corticosteroid users are also excluded. * mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator. inclusion criteria (part ii, patients with opd): * patients with oligo-progression disease (1-3 progression lesions in 1-2 organs) when developing acquired resistance to ici. * radiotherapy to at least one of the opd lesions is indicated in the opinion of the investigator. at least one of the irradiated lesion(s) should be evaluable according to recist 1.1. * ecog ps 0-2. * life expectancy of more than 3 months. * complete radiological information of all lesions during the follow-up. * patients with a prior history of surgery are eligible if they have recovered adequately from the toxicity and/or complications of surgery. * adequate bone marrow function within 1 week prior to the enrollment: hemoglobin ≥80g/l, white blood cell (wbc) count ≥ 4.0 \* 10 \^ 9/l or neutrophil count ≥ 1.5 \* 10 \^ 9/l, and platelet count ≥ 100 \* 10 \^ 9/l; * ability to understand and willingness to provide the informed consent. exclusion criteria (part ii): * secondary malignancy. * histology transformation to non-nsclc. * ineligible for radiotherapy in the opinion of the investigator. or none of the opd are evaluable by recist 1.1. * ecog ps 3 or worse. * short life expectancy (less than 3 months). * unable to provide complete radiological information of lesions. * inadequate bone marrow function. * cannot understand or unwilling to provide the informed consent.
efficacy and safety study of finacea to treat acne vulgaris and post-inflammatory hyperpigmentation (pih)

Conditions: Acne Vulgaris; Post Inflammatory Hyperpigmentation

Summary: residual post-inflammatory hyperpigmentation (pih)from acne is disturbing to individuals with skin of color. finacea has been anecdotally known to be beneficial in resolving pih related to acne vulgaris. however, it has not been clinically tested for this purpose. the current study will investigate the efficacy and safety of finacea in the treatment of acne vulgaris and pih.


Eligibility criteria:
inclusion criteria: * male or female, at least 12 years of age * female subjects of childbearing potential must have a negative urine pregnancy test at baseline * fitzpatrick skin type iv to vi * acne iga (investigator global assessment) score of 2 or 3 * inflammatory lesions of 15-60 (with no more than 2 nodules) * non-inflammatory lesions of 20-100 * post inflammatory hyperpigmentation investigator global assessment (pih iga) score of 3,4 or 5 * able to understand the requirements of the study and sign informed consent/hipaa forms. subjects under the legal age of consent must have the written informed consent of a parent or legal guardian exclusion criteria: * female subjects who are pregnant, breast-feeding or who are of childbearing potential and not practicing a reliable method of birth control * allergy or sensitivity to any component of the test medication * subjects who have not complied with the wash out periods for prohibited medications * medical condition that contraindicates participation * skin disease/disorder that might interfere with the diagnosis of acne vulgaris or pih * evidence of recent alcohol or drug abuse * history of poor cooperation, non-compliance or unreliability * exposure to an investigational drug study within 30 day of baseline visit
atx study:a study of avastin (bevacizumab), tarceva (erlotinib) and xeloda (capecitabine) in patients with locally advanced and/or metastatic pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this 2 part study will evaluate the safety and efficacy of a combination of avastin, tarceva and xeloda (atx) as second-line treatment in patients with locally advanced and/or metastatic pancreatic cancer. in the first part of the study, cohorts of patients will receive escalating doses of combination treatment to determine the maximum tolerated dose. the recommended dose will be used in the second part of the study to determine the efficacy of the atx regime, in terms of its effect on disease progression. the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * pancreatic cancer with locally advanced and/or metastatic disease (stage iv); * chemonaive for metastatic or locally advanced disease; * ecog performance status of 0-2. exclusion criteria: * local (stage ia to iib)and locally advanced (stage iii) pancreatic cancer; * previous exposure to avastin, tarceva or xeloda; * other primary tumor within the last 5 years prior to enrollment, except for adequately treated cancer in situ of cervix, or basal cell skin cancer; * current or recent chronic use of aspirin (\>325 mg/day) or full therapeutic dose of anticoagulants or thrombolytic agents.
neoadjuvant nab-paclitaxel and s-1 in borderline resectable pancreatic cancer

Conditions: Borderline Resectable Pancreatic Cancer

Summary: this study was a single-arm multicenter prospective phase ii clinical study, designed to evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with s-1 in patients with borderline resectable pancreatic cancer. a total of 60 subjects who meet the criteria will receive neoadjuvant chemotherapy of nab-paclitaxel and s-1, for a maximum of 4 cycles prior to pancreatectomy. the primary endpoint is r0 resection rate, the secondary endpoints include overall survival and response rate.


Eligibility criteria:
inclusion criteria: 1. patients have good compliance, can understand the research process of this study, and sign a written informed consent 2. patients with pathologically confirmed pancreatic adenocarcinoma. 3. patients who have not received prior chemotherapy, radiotherapy or other systematic treatment for pancreatic cancer; 4. patients with borderline resectable pancreatic cancer ( nccn version 1，2019 criteria). 5. ecog ps 0-1; 6. tumor size is measurable according to recist1.1 criteria 7. expected survival over 3 months; 8. bone marrow function: neutrophils≥1.5x109/l, platelets ≥100x109/l, hemoglobin≥ 90g/l; 9. liver and kidney function: serum creatinine≤1.5ult; ast and alt≤ 2.5 ult; total bilirubin ≤ 1.5 ult; 10. no contraindications to the use of s-1 and nab-paclitaxel. exclusion criteria: 1. ≥ grade 2 existing peripheral neuropathy; 2. any other malignancy within 5 years prior to enrollment, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, bladder, or nonmelanomatous skin cancer. 3. active, uncontrolled infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate treatment. 4. severe, active co-morbidity, defined as follows: unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months transmural myocardial infarction within the 6 months of study registration uncontrolled hypertension, diabetes or arrhythmia. chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization. 5. not able to take medicine orally. 6. pregnancy or lactation, and women of childbearing age who refused to take appropriate contraceptive measures during the course of this study; 7. participation in other clinical trial within 30 days before the first dose of the drug;
exploratory study of sunitinib malate as a component of neoadjuvant therapy for breast cancer

Conditions: Breast Cancer

Summary: the combination of paclitaxel, doxorubicin, and cyclophosphamide is a standard neoadjuvant (given before surgery) treatment for patients that have either inoperable or operable breast cancer. this treatment can help shrink the tumors so they can be removed to help prevent the cancer from spreading to other parts of the body. this study is being done to test the impact of adding sunitinib as a single-agent (segment 1), followed by sunitinib plus paclitaxel (segment 2), followed by doxorubicin and cyclophosphamide (segment 3). we hope the addition of sunitinib will make the treatment more effective, but we don't know if this is true.


Eligibility criteria:
inclusion criteria: 1. patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor \> 1.0 cm), ii or iii disease. 2. measurable disease by physical examinations or diagnostic breast imaging (mammography, ultrasonography or mr). 3. pre-treatment core or incisional biopsy. patients may not have had definitive primary surgery. 4. male or female, 18 years of age or older. 5. ecog performance status 0 or 1. 6. adequate organ function as defined in the protocol. exclusion criteria: 1. prior radiation therapy, cytotoxic therapy or systemic therapy for breast cancer. prior use of tamoxifen or raloxifene as chemoprevention is allowed but must be discontinued prior to study entry. 2. metastatic (stage iv) breast cancer 3. patients who have had only a pre-treatment fine needle aspiration (fna) are excluded. 4. current therapeutic treatment on another clinical trial with an investigational agent. 5. any of the following within the 6 months prior to starting study treatment: -myocardial infarction -severe/unstable angina -coronary/peripheral artery bypass graft -congestive heart failure -cerebrovascular accident including transient ischemic attack -pulmonary embolus 6. ongoing cardiac dysrhythmias of nci ctcae grade \>=2, atrial fibrillation of any grade, or qtc interval \>450 msec for males or \>470 msec for females. 7. hypertension that cannot be controlled by medications. 8. current treatment with therapeutic doses of any anti-coagulant. prophylactic use of anticoagulants is allowed. 9. known human immunodeficiency virus (hiv) infection. 10. pregnancy or breastfeeding. all female patients with reproductive potential must have a negative pregnancy test prior to first day of study medication. 11. other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Keywords: newly diagnosed breast cancer neoadjuvant therapy
lactopres:study on the effect of dairy peptides on blood pressure in untreated hypertensive subjects.

Conditions: Hypertension

Summary: hypertension is an increasingly important medical and public health issue. literature suggests that there may be a role for dairy foods in the prevention and treatment of hypertension. recently, it has been suggested that several peptides in milk proteins could have blood pressure lowering properties. lactopres is a randomised, double-blind parallel trial to assess the blood pressure effect of an increased intake of dairy peptides in humans.


Eligibility criteria:
inclusion criteria: * systolic blood pressure \>= 140 mmhg * bmi between 18 and 32 kg/m2 * apparently healthy exclusion criteria: * antihypertensive medication * medically prescribed or slimming diet * lactating, pregnant * irregular pulse

Keywords: hypertension blood pressure dairy peptides bioactive peptides randomized controlled trial
a musculoskeletal ultrasound course for orthopedic surgery residents

Conditions: Tendon Disorder

Summary: a group of orthopedic surgery residents underwent a structured online and practical musculoskeletal ultrasound course. their proficiency on a written and practical exam, as well as frequency and comfort when using was recorded prior to the course, immediately after, and 6 months after the course.

musculoskeletal ultrasound (msk-us) can have many uses for orthopedic surgeons, such as assisting in clinical diagnosis for muscle, tendon and ligament injuries, providing direct guidance for joint injections, or assessing the adequacy of a reduction in the emergency department. however, proficiency in sonography is not a requirement for certification in orthopedic surgery in canada, and orthopedic trainees are rarely exposed to the subject. this project aims assess the usefulness in clinical education of a newly implemented msk-us course in an orthopedic surgery program. an msk-us course for orthopedic surgery residents has been developed. an online survey covering the level of training of the resident, their prior experience with ultrasound (number of times used by month) and their comfort level with different parts of the examination (numeric analog scale - nas), was filled by the participants prior to the course. a pre-course written and practical test was also given to the residents. following the course, the participants were reassessed with the same tests and surveys on the same day as the course, and at 6 months post. change in frequency of use, comfort level and test scores were assessed using a kruskal-wallis anova and post-hoc wilcoxon tests. it was expected that residents' frequency of use, comfort level and tests scores would improve following the implementation of the course. the results were expected to be maintained at the 6 months endpoint.

Eligibility criteria:
inclusion criteria: * be an orthopedic surgery resident * training at the university of manitoba * post-graduate year (pgy) one to five exclusion criteria: * residents having less than six months of training left before graduation * residents on extended leave (for example: completing graduate studies abroad, parental leave, and sabbatical)

Keywords: point of care ultrasound musculoskeletal ultrasound sonography resident education orthopaedic surgery online curriculum
appetite regulation by human chemosignals from tears and plasma

Conditions: Obesity

Summary: obesity is closely related to metabolic diseases and its prevalence is sharply increasing. however, there is no safe and effective treatment for obesity so far, the investigators need a breakthrough idea to curtail the constant threat of obesity. it has been recently demonstrated that emotional tears of women can modify sexual responses, one of basic instincts, in men. as appetite and food intake is another basic instinct, chemosignals from tears and plasma may modify appetite and eating behavior in humans.


Eligibility criteria:
inclusion criteria: * woman: negative for hiv, syphilis (vdrl), and hepatitis b and c * man: has a body mass index (bmi) of 18.5 kg/m2 to 27 kg/m2, inclusive. exclusion criteria: * woman: has eyelids inflammation, conjunctivitis, keratitis, lacrimal duct obstruction. has skin diseases around eyes. * man: has diabetes mellitus or dyslipidemia on medication. received gastrointestinal surgery except appendectomy and hemorrhoidectomy.

Keywords: emotional tears postprandial plasma chemosignal obesity appetite food intake